NCI
DiaCarta to Explore XNA Clamp Tech for Low-Frequency Mutations Under NIH Collaboration
Working under a two-year cooperative R&D agreement, the firm will explore its platform for cancer and rare disease mutation detection and in situ cancer cell analyses.
NIH Awards $73M to Continue Buildout of ClinGen
NHGRI and NCI are supplying the funds over five years to teams at five institutions that have been leading the ClinGen effort since its initial inception in 2013.
Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients
Patients will be randomized to receive various chemotherapy regimens depending on how Signatera identifies their minimal residual disease status.
Lung Cancers in Non-Smokers Fall Into Informative Molecular Subtypes
Whole-genome sequencing of lung cancers in never smokers highlighted three copy number-based subtypes, along with alterations linked to patient outcomes.
Blood Testing Distinguishes Benign Tumors From Precancerous Condition
Researchers used ultra-low-pass whole genome sequencing and cell-free DNA fragment size selection to detect pre-cancer in neurofibromatosis type 1 patients.